Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CG Oncology NMIBC data

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Dec 01, 2022 6:12pm

186 Views

Post# 35144751

RE:RE:RE:RE:CG Oncology NMIBC data

Just imagine if we would administer our treatment as often as this, instead of only 2 doses:

receive intravesical CG0070 at 1 x 1012 vp plus IV pembrolizumab at 400 mg once every 6 weeks. CG0070 was administered weekly for 6 weeks as induction, followed by weekly maintenance instillations for 3 weeks at months 3, 6, 9, 12, and 18. Patients who have persistent CIS or high-grade Ta disease at 3 months were permitted to re-induction with CG0070 weekly for 6 additional weeks. Pembrolizumab treatment continued for up to 24 months.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario